HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase I Trial of Immunoliposome HF158K1 for Treatment of HER2 Low and HER2+ Cancers

The company will conduct a Phase I multi-regional, open-label, clinical trial in patients who have advanced refractory solid tumors with HER2 low and HER2+ expression. HER2 expressing solid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers.